OS8.4 Impact of brain invasion assessment on outcome in intracranial grade II meningiomas

Por Picart, T, Dumot, C, Ducray, F, Durand, A, Guyotat, J, Berhouma, M, Meyronet, D
Publicado no Neuro Oncol (2019)

P14.127 From next generation sequencing and comparative genomic hybridization to personalised medicine for adult primary brain tumors: the profiler trial

Por Bonneville-levard, A, Frappaz, D, Pissaloux, D, Wang, Q, Perol, D, Blay, J, Meyronet, D
Publicado no Neuro Oncol (2019)

Spectral complexity of 5-ALA induced PpIX fluorescence in guided surgery: a clinical study towards the discrimination of healthy tissue and margin boundaries in high and low grade...

Por Alston, L., Mahieu-Williame, L., Hebert, M., Kantapareddy, P., Meyronet, D., Rousseau, D., Guyotat, J., Montcel, B.
Publicado no Biomed Opt Express (2019)

P14.88 Comparison of SNaPshot PCR and digital droplet PCR for the identification of TERT promoter in non-diagnostic biopsies from glioma patients

Por Poncet, D, Picart, T, Guyotat, J, Jouanneau, E, Joubert, B, Vasiljevic, A, Honnorat, J, Meyronet, D, Ducray, F, Barritault, M
Publicado no Neuro Oncol (2019)

P01.120 Importance of systematic TERT promoter and IDH mutations screening in non-diagnostic biopsies from patients​ with a suspected glioma

Por Barritault, M, Picart, T, Poncet, D, Fenouil, T, Guyotat, J, Jouanneau, E, Joubert, B, Vasiljevic, A, Honnorat, J, Meyronet, D, Ducray, F
Publicado no Neuro Oncol (2018)

OS5.4 Characteristics of adult diffuse H3K27M-mutant gliomas at recurrence

Por Hodroj, K, Meyronet, D, Barritault, M, Bourg, V, Cohen-Moyal, E, Cartalat, S, Ameli, R, Berhouma, M, Honnorat, J, Ducray, F
Publicado no Neuro Oncol (2019)

OS5.5 Characteristics of high-grade gliomas with H3 G34 mutation in adults

Por Picart, T, Barritault, M, Tabouret, E, Idbaih, A, Izquierdo Gracia, C, Poncet, D, Honnorat, J, Meyronet, D, Guyotat, J, Ducray, F
Publicado no Neuro Oncol (2019)

P14.13 Incidence of pseudoprogression in high-grade IDH-mutant gliomas

Por SEYVE, A, Cartalat, S, Meyronet, D, D’hombres, A, Barritault, M, Jouanneau, E, Berhouma, M, Guyotat, J, Honnorat, J, Ducray, F
Publicado no Neuro Oncol (2019)

P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients

Por Bonnet, C., Cartalat-Carel, S., Thomas, L., Joubert, B., Meyronet, D., D’Hombres, A., Jouanneau, E., Guyotat, J., Honnorat, J., Ducray, F.
Publicado no Neuro Oncol (2016)

P08.39 Characteristics of adults’ gliomas with H3-K27M mutations

Por Esteban Mader, M., Bonnet, C., Meyronet, D., Joly, M., Uro-Coste, E., Forest, F., Guyotat, J., Jouvet, A., Honnorat, J., Ducray, F.
Publicado no Neuro Oncol (2016)

OS3.3 Radiological characteristics and natural history of adult IDH wild type astrocytomas with TERT promoter mutations

Por Izquierdo, C, Barritault, M, Poncet, D, Cartalat, S, Joubert, B, Bruna, J, Jouanneau, E, Guyotat, J, Vasiljevic, A, Fenouil, T, Berthezène, Y, Honnorat, J, Meyronet, D, Ducray, F
Publicado no Neuro Oncol (2018)

P13.02 Conventional MRI radiomics in the diagnosis of early- and pseudo-progression

Por Bani Sadr, A, Eker, O F, Berner, L, Ameli, R, Hermier, M, Barritault, M, Meyronet, D, Guyotat, J, Jouanneau, E, Honnorat, J, Ducray, F, Berthezène, Y
Publicado no Neuro Oncol (2019)